MDK and hepatocellular carcinoma: To verify the role of nanodrugs in conquering ICB resistance for HCC treatment, mice bearing orthotopic HCC were administered different therapies (siRNA@NP, aPD-1@NP, or the combination of MDK-siRNA and aPD-1, i.e., aPD-1-siRNA@NP) via tail vein injection [24].